• Home >>
  • Pharmaceuticals and Healthcare >>
  • Cephalosporin Drugs Global Market Synopsis, Growth Factors, Industry Segmentation, Regional Analysis And Competitive Analysis 2017 - 2025

Cephalosporin Drugs Global Market Synopsis, Growth Factors, Industry Segmentation, Regional Analysis And Competitive Analysis 2017 - 2025

ID: 231346 May, 2018 Region : Global Pages Reports Monitor

Cephalosporin Market Type (Branded, Generics), by Generation (First-generation to Fifth-generation), Route of Drug Administration (Oral, Injection), Application (Sexually Transmitted Infection, Respiratory Tract Infection) - Global forecast till2025
Market Overview

Cephalosporin is wide class of beta-lactam anti-toxin use to battle bacterial contamination by disturbing peptidoglycan build-up principally exhibit in the cell wall of the bacterium. The cephalosporin anti-microbial is initially acquired from the fungus Acremonium which earlier used to be known as cephalosporium. It is utilized as a part of the treatment against staphylococcus contamination, tonsillitis, bronchitis, skin diseases, strep throat, gonorrhea, pneumonia, skin diseases, otitis media and some more. Cephalosporins are sorted into ages relying on their range of antimicrobial action. Original of cephalosporin was dynamic against gram positive organisms, however with fresher progressive age it has expanded movement against gram negative microorganisms with relatively lessened action against gram positive once. In any case, the fourth era cephalosporins have genuine expansive range action.


Special regulatory designation for pipeline molecules, high spending on research and improvement exercises , upsurge in frequency of irresistible ailments, ascend in financing for the advancement of anti-infection agents, and rising requirement for antagonistic substances to kill bacteria are the key components driving the expansion of this market. Nonetheless, contradictory side effects associated with cephalosporin including oral & vaginal candidiasis, vomiting, headache, nausea, diarrhoea and numerous others limits the further market development. Likewise, with each successive generation resistance shown by the organism is lessening the effect of cephalosporin as broad spectrum anti-microbial hampering the growth of the market. 


Segmentation
The global cephalosporin market is differentiated based on type, generation, route of administration, application and geography. In terms of type the market is segmented into generic cephalosporin drug and branded cephalosporin drug.  On the basis of generation market is separated into first, second, third, fourth and fifth generation. Depending upon route of administration the market is categorized into oral cephalosporin drug and cephalosporin injections. In terms of application market is differentiated into sexually transmitted infection, urinary tract infection, ear infection, Skin infection, respiratory infection and many others. 


Regional Analysis
Considering global scenario of the cephalosporin the market is analysed into North America, Europe, Asia-Pacific, Latin America and Middle East and Africa. Large population base of China followed by India supports the growth of Asian-Pacific countries.  Other factors contributing to the growth of this region includes high disposable income, existing unmet medical needs and increased awareness among patients related to cephalosporin drugs. North America is expected to be the most attractive market by region in upcoming years owing to rising prevalence of infectious disease.


Key Players
The major players performing in the market are Allergan, Astellas, Bristol-Myers Squibb, GlaxoSmithKline, Merck & Co., Inc., Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd., Pfizer, Sandoz, Lupin Pharmaceuticals. Other Prominent Vendors include Eli Lilly, Biocon, Johnson & Johnson, Sanofi and Takeda Pharmaceuticals.


Global Cephalosporin Market Segmentation
• By Type
 Generic Cephalosporin Drugs
 Branded Cephalosporin Drugs


• By Generation
 First Generation
 Second Generation
 Third Generation
 Fourth Generation
 Fifth Generation


• By Route of Administration
 Oral Cephalosporin Drugs
 Cephalosporin Injection


• By Application
 Sexually transmitted infection
 Urinary tract infection
 Ear infection
 Skin infection
 Respiratory tract infection


• By Geography
o North America
 US 
 Canada
 Mexico
o Europe
 UK
 France
 Italy
 Germany
 Spain
 Rest of Europe
o Asia-Pacific
 India
 China
 Japan
 Australia
 Rest of APAC
o LAMEA
 South Africa
 Brazil
 Saudi Arabia


• Market Key Players
 Allergan
 Astellas
 Bristol-Myers Squibb
 GlaxoSmithKline
 Merck & Co., Inc.
 Hoffmann-La Roche Ltd
 Teva Pharmaceutical Industries Ltd.
 Pfizer
 Sandoz
 Lupin Pharmaceuticals
• Other Prominent Vendors
 Eli Lilly
 Biocon
 Johnson & Johnson
 Sanofi
 Takeda Pharmaceuticals

Research Scope
The study for Global Cephalosporin Drugs Market will provide market size, estimates and forecast based on the following years: 
 
Historic data: 2015  Base Year Estimate: 2016  Forecast: 2017 to 2025


The report has been categorized in two distinctive sections, where the first category titled as Market Overview provides a holistic view of the market, key trends, drivers, challenges/restraints or opportunities with their current and expected impact on the overall industry sales. 
Our analyst implement several qualitative tools such as Ansoff’s Matrix, PESTEL analysis, Porter’s five force analysis among other to interpret and represent key industry findings. 
The second section of the study provides market size, estimates and forecast for key market segments and regional market. The final part of the report highlights key manufacturers/vendors operating in the associated market. 


1. Introduction
1.1. Market Definition
1.2. Market Scope


2. Research Methodology
2.1. Primary Research
2.2. Secondary Sources
2.3. Assumptions & Exclusions


3. Market Overview
3.1. Research Report Segmentation & Scope
3.2. Key Market Trend Analysis
3.2.1. Market Drivers
3.2.2. Market Restraint/Challenges
3.2.3. Market Opportunities
3.3. Porter’s Five Forces Analysis
3.4. Potential Venture Avenues
3.5. Market Share Analysis, 2016 


4. Type Overview
4.1. Introduction
4.2. Market Size & Forecast, 2015 to 2025
4.2.1. Generic Cephalosporin Drugs
4.2.2. Branded Cephalosporin Drugs
 (Note: The segments mentioned above are tentative in nature and are subject to change as the research progresses)


5. Generation Overview
5.1. Introduction
5.2. Market Size & Forecast, 2015 to 2025
5.2.1. First Generation
5.2.2. Second Generation
5.2.3. Third Generation
5.2.4. Fourth Generation
5.2.5. Fifth Generation
 (Note: The segments mentioned above are tentative in nature and are subject to change as the research progresses)


6. Route of Administration Overview
6.1. Introduction
6.2. Market Size & Forecast, 2015 to 2025
6.2.1. Oral Cephalosporin Drugs
6.2.2. Cephalosporin Injection
 (Note: The segments mentioned above are tentative in nature and are subject to change as the research progresses)


7. Application Overview
7.1. Introduction
7.2. Market Size & Forecast, 2015 to 2025
7.2.1. Sexually transmitted infection
7.2.2. Urinary tract infection
7.2.3. Ear infection
7.2.4. Skin infection
7.2.5. Respiratory tract infection
 (Note: The segments mentioned above are tentative in nature and are subject to change as the research progresses)


8. Regional Overview
8.1. Introduction
8.2. Market Size & Forecast, 2015 to 2025
8.2.1. North America
8.2.1.1. U.S.
8.2.1.2. Canada
8.2.1.3. Mexico
8.2.2. Europe
8.2.2.1. UK
8.2.2.2. Germany
8.2.2.3. France
8.2.2.4. Italy 
8.2.2.5. Spain
8.2.2.6. Turkey
8.2.2.7. Rest of Europe
8.2.3. Asia-Pacific
8.2.3.1. China
8.2.3.2. India
8.2.3.3. Japan
8.2.3.4. South Korea
8.2.3.5. Rest of Asia-Pacific
8.2.4. LAMEA
8.2.4.1. Brazil
8.2.4.2. Saudi Arabia
8.2.4.3. South Africa
8.2.4.4. Rest of LAMEA
 (Note: The segments mentioned above are tentative in nature and are subject to change as the research progresses)


9. Manufacturer/ Vendor Profile
9.1. The following attributes will be considered while profiling key manufacturers in this industry: 
9.1.1. Company Overview
9.1.2. Financial Synopsis
9.1.3. Recent Developments
9.1.4. R&D Investments (if any)
9.1.5. Strategy Overview (Analyst Perspective)
9.1.6. Product Portfolio
9.2. Companies Profiled
9.2.1. Allergan
9.2.2. Astellas
9.2.3. Bristol-Myers Squibb
9.2.4. GlaxoSmithKline
9.2.5. Merck & Co., Inc.
9.2.6. Hoffmann-La Roche Ltd
9.2.7. Teva Pharmaceutical Industries Ltd.
9.2.8. Pfizer
9.2.9. Sandoz
9.2.10. Lupin Pharmaceuticals
 (Note: The companies mentioned above are tentative in nature, and profiles of other market players not listed here can be included on request.)

Request Sample

Name*

Email*

Phone*

Name of the Company*

Title/ Designation*

Select Country*

How can we help you?

Request Discount

Name*

Email*

Phone*

Name of the Company*

Title/ Designation*

Select Country*

How can we help you?

Related Reports




Get 15 minutes of free Consultation When you request a Sample Report!

24/7 Research Report

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone:

+1 513 549 5911 (US)

+44 203 318 2846 (UK)

Email: [email protected]